TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17545090

Group type: EXPERIMENTAL
Intervention: Intubation at 1 min after rocuronium administration
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intubation at 2-4 min after rocuronium administration
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Suppression of neuromuscular function at 1 min after rocuronium administration
Number of subjects: 120
Study: 15336770

Group type: EXPERIMENTAL
Intervention: Atridox (doxycycline)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (no Atridox)
Number of subjects: 28
Study: 11118390

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis (primary and secondary) for Pneumocystis carinii pneumonia
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis for Mycobacterium avium complex
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis for cytomegalovirus
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Treatment for wasting
Number of subjects: 531
Study: 9688002

Group type: EXPERIMENTAL
Intervention: Oral iron supplements (320 mg twice daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 10207294

Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg/day and heparansulphate 200 mg/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Indobufen 200 mg/day
Number of subjects: 19
Study: 1929130

Group type: EXPERIMENTAL
Intervention: Nasogastric decompression
Number of subjects: 197

Group type: COMPARATOR
Intervention: No nasogastric decompression
Number of subjects: 197
Study: 6356903

Group type: EXPERIMENTAL
Intervention: Labetalol alone or in combination with furosemide
Number of subjects: 81

Group type: COMPARATOR
Intervention: Methyldopa plus furosemide
Number of subjects: 81
Study: 31313297

Group type: EXPERIMENTAL
Intervention: Adult Resilience Program (ARP)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 76
Study: 31532789

Group type: EXPERIMENTAL
Intervention: DNA-IIV3 (trivalent hemagglutinin DNA prime followed by trivalent inactivated influenza vaccine boost with a 3.5 month interval, administered intradermally)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: IIV3-IIV3 (IIV3 prime followed by IIV3 boost with a 10 month interval, administered intramuscularly)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: DNA/IIV3-IIV3 (concurrent DNA and IIV3 prime followed by IIV3 boost with a 10 month interval)
Number of subjects: 316

Group type: COMPARATOR
Intervention: IIV3 administered by ID route
Number of subjects: 316

Group type: COMPARATOR
Intervention: IIV3 administered by IM route
Number of subjects: 316

Group type: COMPARATOR
Intervention: DNA vaccine administered by Biojector
Number of subjects: 316
Study: 27918240

Group type: COMPARATOR
Intervention: Morning testing (AM; 9:00 h)
Number of subjects: 13
Study: 27073876

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D3 (per 10 nmol/L)
Number of subjects: 2877

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D3
Number of subjects: 2877
Study: 24326593

Group type: EXPERIMENTAL
Intervention: Deltoid-split approach
Number of subjects: 120

Group type: COMPARATOR
Intervention: Deltopectoral approach
Number of subjects: 120
Study: 22289854

Group type: EXPERIMENTAL
Intervention: Aggressive phototherapy
Number of subjects: 174

Group type: COMPARATOR
Intervention: Conservative phototherapy
Number of subjects: 174
Study: 20645078

Group type: EXPERIMENTAL
Intervention: Methylphenidate (mean: 14.7 mg; range: 10‐30 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17931510

Group type: EXPERIMENTAL
Intervention: Criterion-based training using surgical simulators
Number of subjects: 17
Study: 15819974

Group type: EXPERIMENTAL
Intervention: ABC/EFV/ddI plus HU (500 mg twice daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: ABC/EFV/ddI without HU
Number of subjects: 54
Study: 11990302

Group type: EXPERIMENTAL
Intervention: Pegaspargase
Number of subjects: 27

Group type: COMPARATOR
Intervention: Native E. coli L-asparaginase
Number of subjects: 27
Study: 9139177

Group type: EXPERIMENTAL
Intervention: Arm crank exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cycle exercise
Number of subjects: 8
Study: 8444395

Group type: EXPERIMENTAL
Intervention: Single-dose ciprofloxacin 250 mg p.o.
Number of subjects: 226

Group type: COMPARATOR
Intervention: Two-day treatment with ciprofloxacin 250 mg bid
Number of subjects: 226

Group type: COMPARATOR
Intervention: Three-day treatment with ciprofloxacin 2 x 250 mg/day
Number of subjects: 226
Study: 2431013

Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin at 0.25 U/ml
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin at 0.5 U/ml
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin at 1 U/ml
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin (all concentrations)
Number of subjects: 26
Study: 30252913

Group type: EXPERIMENTAL
Intervention: Metformin DR 1200 mg
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Metformin DR 1500 mg
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Metformin IR 1000 mg
Number of subjects: 571

Group type: COMPARATOR
Intervention: Placebo (QD)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Metformin DR (normalized efficacy)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Metformin DR
Number of subjects: 571
Study: 26468213

Group type: EXPERIMENTAL
Intervention: Telemedicine (home treatment by video conferences)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard outpatient treatment
Number of subjects: 40
Study: 24478238

Group type: EXPERIMENTAL
Intervention: Prototype group
Number of subjects: 37
Study: 22652012

Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 104

Group type: COMPARATOR
Intervention: No reminders
Number of subjects: 104
Study: 20400409

Group type: EXPERIMENTAL
Intervention: Tipranavir (1250/100 mg) + Ritonavir
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Tipranavir (750/100 mg) + Ritonavir
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Tipranavir (250/200 mg) + Ritonavir
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Tipranavir + Ritonavir
Number of subjects: 208
Study: 18507270

Group type: EXPERIMENTAL
Intervention: Non-White women
Number of subjects: 378

Group type: COMPARATOR
Intervention: Control group (White women)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Angiographic disease progression
Number of subjects: 378

Group type: COMPARATOR
Intervention: Survival without myocardial infarction
Number of subjects: 378
Study: 15852175

Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound examination for PCL insufficiency (mfix)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound examination for PCL insufficiency (ofix)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound examination for ACL insufficiency
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound examination for ACL insufficiency (spontaneous ventral tibia translation)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound examination for ACL insufficiency (normal resting value)
Number of subjects: 40
Study: 12458862

Group type: EXPERIMENTAL
Intervention: Tecnis Z9000 intraocular lens (Pharmacia)
Number of subjects: 2

Group type: COMPARATOR
Intervention: AMO AR40e Opti‐Edge intraocular lens (AMO)
Number of subjects: 2
Study: 10488481

Group type: EXPERIMENTAL
Intervention: 200 micrograms iodide/day
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: 1.53 milligrams iodide/week
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: up to 200 micrograms iodide/day
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: suppressive hormone administration
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: combination of non-suppressive hormone therapy with low dose iodide (50-150 micrograms/day)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: mere iodide in doses of 200 micrograms/day
Number of subjects: 752

Group type: COMPARATOR
Intervention: no therapy
Number of subjects: 752
Study: 8703875

Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C (0.2 mg/ml solution for 3 minutes)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (surgical excision only)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study: 1499364

Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (10-40 mg/d), enalapril (5-20 mg/d), and hydrochlorothiazide (12.5-25 mg/d) as necessary.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (matching placebos to active treatment).
Number of subjects: 0
Study: 6089633

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 195

Group type: COMPARATOR
Intervention: Nafcillin plus tobramycin
Number of subjects: 195
Study: 31280991

Group type: EXPERIMENTAL
Intervention: Blindfold training (routine practice + blindfold training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine practice (control group)
Number of subjects: 0
Study: 30304714

Group type: EXPERIMENTAL
Intervention: Proactive, high-dose IV iron (iron sucrose 400 mg/month unless ferritin > 700 μg/L and/or TSAT ≥40%)
Number of subjects: 2141

Group type: COMPARATOR
Intervention: Reactive, low-dose IV iron (iron sucrose administered if ferritin <200 μg/L or TSAT < 20%)
Number of subjects: 2141

Group type: EXPERIMENTAL
Intervention: Proactive, high-dose IV iron
Number of subjects: 2141

Group type: COMPARATOR
Intervention: Reactive, low-dose IV iron
Number of subjects: 2141
Study: 26962013

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (standard best practice clinical care)
Number of subjects: 68
Study: 24090048

Group type: EXPERIMENTAL
Intervention: Sacha inchi oil (10 or 15 ml)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sunflower oil (10 or 15 ml)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both oils
Number of subjects: 18
Study: 22751085

Group type: EXPERIMENTAL
Intervention: levodopa/benserazide, 100/25 mg with domperidone, 10 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: levodopa/benserazide, 100/25 mg
Number of subjects: 18
Study: 20920365

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169

Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 169
Study: 17566120

Group type: EXPERIMENTAL
Intervention: Isosmotic macrogol electrolyte solution (MC-ES)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 15598680

Group type: EXPERIMENTAL
Intervention: Growth hormone (0.67 mg/d)
Number of subjects: 40
Study: 12047731

Group type: EXPERIMENTAL
Intervention: Carbamazepine (600-800 mg on day 1 tapering to 200 mg)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Lorazepam (6-8 mg on day 1 tapering to 2 mg)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Carbamazepine (for patients with multiple past detoxifications)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Lorazepam (for patients with multiple past detoxifications)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 136
Study: 9472648

Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy
Number of subjects: 341
Study: 7639218

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) 120 mg
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: CBS plus amoxicillin (500 mg)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: CBS plus metronidazole (400 mg)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: CBS plus metronidazole and amoxicillin
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: CBS plus metronidazole and tetracycline (500 mg)
Number of subjects: 190

Group type: COMPARATOR
Intervention: H. pylori-negative patients
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Patients with recrudescent infection
Number of subjects: 190
Study: 2172401

Group type: EXPERIMENTAL
Intervention: Interferon-alpha preparations (combined)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 790554

Group type: EXPERIMENTAL
Intervention: Ketoprofen (150 mg daily for 14 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Indomethacin (150 mg daily for 14 days)
Number of subjects: 30
Study: 30902750

Group type: EXPERIMENTAL
Intervention: liraglutide 3.0 mg plus phentermine 15.0 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: liraglutide plus placebo
Number of subjects: 45
Study: 29211953

Group type: EXPERIMENTAL
Intervention: Smooth handle toothbrush
Number of subjects: 26

Group type: COMPARATOR
Intervention: Grooved handle toothbrush
Number of subjects: 26
Study: 25438930

Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet
Number of subjects: 0
Study: 22443479

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic-valve replacement (TAVR)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement
Number of subjects: 699
Study: 20537748

Group type: EXPERIMENTAL
Intervention: VAL 320 mg/d
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 18264535

Group type: COMPARATOR
Intervention: Resin modified glass ionomer cement (RMGIC) with conventional Class I cavities
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer cement (RMGIC) with modified cavities (1 mm straight bevel)
Number of subjects: 42
Study: 15853436

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (160 microg/4.5 microg) in a single inhaler
Number of subjects: 1022

Group type: COMPARATOR
Intervention: Budesonide (200 microg)
Number of subjects: 1022

Group type: COMPARATOR
Intervention: Formoterol (4.5 microg)
Number of subjects: 1022

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol
Number of subjects: 1022
Study: 12608965

Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene (PTFE)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Fluoropolymer coated Dacron
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PTFE in patients with critical limb ischaemia
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PTFE in patients with below-knee anastomosis
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PTFE with smaller (6 mm) diameter grafts
Number of subjects: 129

Group type: COMPARATOR
Intervention: Fluoropolymer coated grafts
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: PTFE
Number of subjects: 129
Study: 10475617

Group type: EXPERIMENTAL
Intervention: HIDAC (High Dose Cytarabine)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: HIDAC + M (High Dose Cytarabine plus Mitoxantrone)
Number of subjects: 162
Study: 8568427

Group type: EXPERIMENTAL
Intervention: Activator adjustment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Meric adjustment
Number of subjects: 30
Study: 1775609

Group type: EXPERIMENTAL
Intervention: Carbamazepine 200 mg or 400 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7011362

Group type: EXPERIMENTAL
Intervention: Soya-bean flour with 22 g saponins/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Soya-bean flour with 4 g saponins/kg
Number of subjects: 10
Study: 29143157

Group type: EXPERIMENTAL
Intervention: Disclosure Intervention (DI)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Attention Control Case Management (ACCM)
Number of subjects: 315
Study: 27423902

Group type: EXPERIMENTAL
Intervention: Removal of sweet beverages by the community pharmacy (intervention started on September 11, 2014)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Other food stores in the town (control)
Number of subjects: 123
Study: 25516625

Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin
Number of subjects: 39

Group type: COMPARATOR
Intervention: 10 mg simvastatin plus 10 mg ezetimibe
Number of subjects: 39
Study: 22814383

Group type: EXPERIMENTAL
Intervention: Fine Structure Processing (FSP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: CIS+
Number of subjects: 46

Group type: COMPARATOR
Intervention: HDCIS
Number of subjects: 46
Study: 20829521

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study: 18055183

Group type: EXPERIMENTAL
Intervention: Intermittent infusion (600mg/12h)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continuous infusion (300mg intravenous loading dose + 900mg continuous infusion on Day 1, followed by 1200mg/daily from Day 2)
Number of subjects: 16
Study: 15649191

Group type: EXPERIMENTAL
Intervention: Brivudin (125 mg, once a day for 7 days)
Number of subjects: 2027

Group type: COMPARATOR
Intervention: Famciclovir (250 mg, three times a day for 7 days)
Number of subjects: 2027

Group type: EXPERIMENTAL
Intervention: Brivudin
Number of subjects: 2027

Group type: COMPARATOR
Intervention: Famciclovir
Number of subjects: 2027

Group type: EXPERIMENTAL
Intervention: Brivudin and Famciclovir
Number of subjects: 2027
Study: 12867222

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg, increased to losartan 50 mg/HCTZ 12.5 mg at week 6 and losartan 100 mg/HCTZ 25 mg at week 12
Number of subjects: 857

Group type: COMPARATOR
Intervention: Amlodipine 5 mg, increased to amlodipine 10 mg at week 6 and amlodipine 10 mg/HCTZ 25 mg at week 12
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 857

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 857
Study: 10553839

Group type: EXPERIMENTAL
Intervention: Smart patient-controlled analgesia system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional patient-controlled analgesia system
Number of subjects: 0
Study: 8705639

Group type: EXPERIMENTAL
Intervention: Ovalbumin-stimulated peripheral blood mononuclear cells from egg-sensitive patients
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: IL-2-stimulated peripheral blood mononuclear cells from egg-sensitive patients
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both ovalbumin-stimulated and IL-2-stimulated peripheral blood mononuclear cells from egg-sensitive patients
Number of subjects: 2

Group type: COMPARATOR
Intervention: Nonatopic healthy children
Number of subjects: 2
Study: 1927197

Group type: EXPERIMENTAL
Intervention: Brushing before biopsy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Brushing after biopsy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Biopsy after brushing
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Combined brushing and biopsy
Number of subjects: 300
Study: 6612231

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic treatment with ampicillin 2 g X 4 + cloxacillin 1 g X 4 for 4 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group without antibiotics
Number of subjects: 50
Study: 31771589

Group type: EXPERIMENTAL
Intervention: Intervention (LWTC programme)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 314
Study: 30157835

Group type: EXPERIMENTAL
Intervention: Long axis measurement
Number of subjects: 60
Study: 26968844

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly
Number of subjects: 287

Group type: COMPARATOR
Intervention: Sulfasalazine 3 g daily
Number of subjects: 287
Study: 25876342

Group type: EXPERIMENTAL
Intervention: Warm acupuncture combined with auricular point sticking therapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Estazolam tablets (0.5 to 1 mg)
Number of subjects: 130
Study: 22595139

Group type: EXPERIMENTAL
Intervention: Subcutaneous supplementation of a trace mineral supplement containing Zn, Mn, Se, and Cu at 230 days of gestation and 260 days of gestation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 20662910

Group type: EXPERIMENTAL
Intervention: Low-fluoride toothpaste (500 p.p.m. F)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional toothpaste (1,000-1,500 p.p.m. F)
Number of subjects: 14
Study: 17693150

Group type: EXPERIMENTAL
Intervention: Concentric training (CON)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Eccentric training (ECC)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Untrained limb
Number of subjects: 54
Study: 15536539

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 11900939

Group type: EXPERIMENTAL
Intervention: Collagen/elastin dermal substitute in combination with an autograft
Number of subjects: 29

Group type: COMPARATOR
Intervention: Split-thickness autograft (control)
Number of subjects: 29
Study: 10511608

Group type: EXPERIMENTAL
Intervention: Active treatment with omeprazole (20 mg twice daily), amoxicillin (1000 mg), and clarithromycin (500 mg) for 14 days
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Active treatment and H. pylori-negative patients
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo treatment and H. pylori-positive patients
Number of subjects: 337
Study: 8822429

Group type: EXPERIMENTAL
Intervention: Surgery and oxidized regenerated cellulose barrier (Interceed group, n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Surgery alone (control group, n = 25)
Number of subjects: 50
Study: 2379087

Group type: EXPERIMENTAL
Intervention: Adults with mental handicap (Down's syndrome)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Adults with mental handicap (epilepsy)
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Overall dentate adults with mental handicap
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Adults with mental handicap
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Adults with Down's syndrome
Number of subjects: 382
Study: 7381554

Group type: EXPERIMENTAL
Intervention: CT scan performed at the end of the surgical procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT assessments before initiating radio-chemotherapy and at the completion of each cycle
Number of subjects: 0